Impact of Cyclooxygenase-2 in Breast Cancer

被引：0

作者：

Hoellen, Friederike ^{[1
]}

Kelling, Katharina ^{[1
]}

Dittmer, Christine ^{[1
]}

Diedrich, Klaus ^{[1
]}

Friedrich, Michael ^{[2
]}

Thill, Marc ^{[1
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Gynecol & Obstet, D-23538 Lubeck, Germany

[2] HELIOS Klinikum Krefeld, Krefeld, Germany

来源：

ANTICANCER RESEARCH | 2011年 / 31卷 / 12期

关键词：

Cyclooxygenase; COX-2; breast cancer; tumor; prostaglandin; carcinogenesis; CARCINOMA IN-SITU; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MESSENGER-RNA EXPRESSION; PROSTAGLANDIN METABOLIZING ENZYMES; COX-2 INHIBITOR CELECOXIB; VITAMIN-D-RECEPTOR; CELL-LINES; CYCLO-OXYGENASE-2; COX-2; AROMATASE EXPRESSION; OVARIAN-CARCINOMA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostaglandin metabolism plays a pivotal role in inflammatory processes and has also been demonstrated to have a role in carcinogenesis, tumor differentiation and tumor growth in breast cancer. Cyclooxygenase-2 (COX-2) is the key involved enzyme, as it triggers prostaglandin synthesis. We reviewed the current literature regarding the impact of prostaglandin metabolism on breast cancer and illustrated the current evidence of the COX-2 influence on breast cancer, delineating possible future prophylactic and therapeutic strategies.

引用

页码：4359 / 4367

页数：9

共 101 条

[1] Mode of delivery and neonatal survival of infants with gastroschisis in Australia and New Zealand [J].

Abdel-Latif, Mohamed E. ;

Bolisetty, Srinivas ;

Abeywardana, Samanthi ;

Lui, Kei .

JOURNAL OF PEDIATRIC SURGERY, 2008, 43 (09) :1685-1690

[2] Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: Correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival [J].

Ali-Fehmi, R ;

Morris, RT ;

Bandyopadhyay, S ;

Che, MX ;

Schimp, V ;

Malone, JM ;

Munkarah, AR .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (03) :819-825

[3]

Alshafie GA, 2000, ONCOL REP, V7, P1377

[4] uPA and PAI-1 in breast cancer: Review of their clinical utility and current validation in the prospective NNBC-3 trial [J].

Annecke, K. ;

Schmitt, M. ;

Euler, U. ;

Zerm, M. ;

Paepke, D. ;

Paepke, S. ;

von Minckwitz, G. ;

Thomssen, C. ;

Harbeck, N. .

ADVANCES IN CLINICAL CHEMISTRY, VOL 45, 2008, 45 :31-45

[5] Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer [J].

Barnes, N. L. P. ;

Warnberg, F. ;

Farnie, G. ;

White, D. ;

Jiang, W. ;

Anderson, E. ;

Bundred, N. J. .

BRITISH JOURNAL OF CANCER, 2007, 96 (04) :575-582

[6] A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells [J].

Basu, Gargi D. ;

Liang, Winnie S. ;

Stephan, Dietrich A. ;

Wegener, Lee T. ;

Conley, Christopher R. ;

Pockaj, Barbara A. ;

Mukherjee, Pinku .

BREAST CANCER RESEARCH, 2006, 8 (06)

[7]

Basu GD, 2004, MOL CANCER RES, V2, P632

[8] COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ [J].

Boland, GP ;

Butt, IS ;

Prasad, R ;

Knox, WF ;

Bundred, NJ .

BRITISH JOURNAL OF CANCER, 2004, 90 (02) :423-429

[9] Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor-Selective Retinoid [J].

Brown, Powel H. ;

Subbaramaiah, Kotha ;

Salmon, Amoi P. ;

Baker, Rebecca ;

Newman, Robert A. ;

Yang, Peiying ;

Zhou, Xi Kathy ;

Bissonnette, Reid P. ;

Dannenberg, Andrew J. ;

Howe, Louise R. .

CANCER PREVENTION RESEARCH, 2008, 1 (03) :208-214

[10] A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer [J].

Canney, P. A. ;

Machin, M. A. ;

Curto, J. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) :2751-2756

← 1 2 3 4 5 6 7 8 9 10 →